Clotting defects raise risk of venous thrombosis from the Pill

April 2000
CMAJ: Canadian Medical Association Journal;4/18/2000, Vol. 162 Issue 8, p1197
Academic Journal
Reports that blood clotting defects in women increases the risk of venous thrombosis. Risk of developing thrombosis within the first year of taking oral contraceptives; Risk for women with inherited clotting defects such as protein C deficiency.


Related Articles

  • The risk of deep venous thrombosis with oral contraceptives containing drospirenone: Data are inconclusive, but alternatives may be preferable unless specifically contraindicated. Dunn, Nick // BMJ: British Medical Journal (Overseas & Retired Doctors Edition;4/30/2011, Vol. 342 Issue 7804, p933 

    In this article, the author discusses several researches which have been conducted on risk of developing deep venous thrombosis by consuming oral contraceptives containing drospirenone and contradictory outcome of the researches. He mentions how the researches were performed, their strengths and...

  • Risk of venous thrombosis varies with different types of combined oral contraceptives. DeSancho, Maria T. // Evidence Based Medicine;Apr2014, Vol. 19 Issue 2, pe11 

    The author comments on the article "Different combined oral contraceptives and the risk of venous thrombosis: systematic review and network meta-analysis," by B. H. Stegeman and colleagues in the 2013 issue. Discussion and highlights are given on the variation of venous thrombosis (VT) risk in...

  • An Increased Risk of DVT with Vaginal Ring Contraception -- True or Flawed Studies? Jensen, Jeffrey T. // OB/GYN Clinical Alert;Jul2012, Vol. 29 Issue 3, p17 

    The article offers information on a study regarding the risk of venous thrombosis (VT) after the use of non oral hormonal contraception. The associated risks are even higher in obese women and in those with inherited thrombophilias. The study compares the result with the user of oral hormonal...

  • Third generation oral contraceptives--the controversy. Carnall, Douglas; Karcher, Helmut // BMJ: British Medical Journal (International Edition);12/16/95, Vol. 311 Issue 7020, p1589 

    Reports on the risk of venous thromboembolism for women taking oral contraceptives containing the synthetic progesterones, gestodene and desogestrel. International reactions on the issue.

  • Risk of Venous Thromboembolism. Gundert-Remy, Ursula; Stammschulte, Thomas // Deutsches Aerzteblatt International;11/11/2011, Vol. 108 Issue 45, p768 

    A letter to the editor is presented in response to the article "Hormonal contraception: what kind, when, and for whom?," by I. Wiegratz and C. J. Thaler in the 2011 issue.

  • Combined oral contraceptives increase risk of venous thrombosis according to oestrogen dose and type of progestogen. Sandset, Per Morten // Evidence Based Medicine;Oct2014, Vol. 19 Issue 5, p194 

    The author reflects on the study "Combined oral contraceptives: venous thrombosis" by F Rosendaal and others, in the periodical "Cochrane Database of Systematic Reviews" in 2014. Topics discussed include increases risk of venous thrombosis either deep venous thrombosis or pulmonary embolism from...

  • Oral contraceptive use cited as a risk factor of VTE after hip arthroscopy. Buddle, Renee Blisard // Orthopedics Today;Dec2012, Vol. 32 Issue 12, p31 

    The article discusses a study by Roy I. Davidovitch and colleagues, which revealed that oral contraceptive use was found to be a risk factor of venous thromboembolism (VTE) in patients after hip arthroscopy.

  • Laboratory thrombophilias and venous thromboembolism. Joffe, Hylton V; Goldhaber, Samuel Z // Vascular Medicine;2002, Vol. 7 Issue 2, p93 

    Inherited abnormalities of coagulation are increasingly recognized in patients with venous thromboembolism. Common causes of hypercoagulability, also known as thrombophilia, include factor V Leiden, the prothrombin gene mutation, hyperhomocysteinemia, and antiphospholipid antibodies....

  • In Reply. Wiegratz, Inka; Thaler, Christian // Deutsches Aerzteblatt International;11/11/2011, Vol. 108 Issue 45, p769 

    A response by I. Wiegratz and C. J. Thaler in a letter to the editor regarding their article "Hormonal contraception: what kind, when, and for whom?" in the 2011 issue is presented.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics